Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.55 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133972 | 0.92 | ATM (0.61) | SGMS2NPC1HTTGAALMNA | |
| SCHEMBL27595889 | 0.92 | SGMS2 (0.57) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL8670382 | 0.91 | SGMS2 (0.60) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL112903 | 0.89 | SGMS2 (0.66) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL29433417 | 0.89 | SGMS2 (0.66) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL8786705 | 0.87 | SGMS2 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL17799483 | 0.87 | SGMS2 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| Hydrochloric Acid SCHEMBL8998291 | 0.87 | SGMS2 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| Bicarbonate SCHEMBL21753662 | 0.87 | SGMS2 (0.64) | SGMS2NPC1HTTGAAPARP1 | |
| Bicarbonate SCHEMBL236872 | 0.87 | SGMS2 (0.64) | SGMS2NPC1HTTGAAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785436-B2 | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2709992-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012156284-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| EP-0498770-A1 | Certain benzodioxole, benzodioxane and benzodioxepin derivatives | CIBA-GEIGY AG (CH) | 1992-08-12 | — | — | EP | disclosed |
| US-5120758-A | Treating allergic, inflammatory, cardiovascular, pulmonary, arthritic, cutaneous disorders | CIBA-GEIGY CORPORATION (US) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SGMS2 2506/4885NPC1 265/4885HTT 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.